Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report
Switch from dabrafenib/trametinib combination therapy to encorafenib/binimetinib combination therapy with transition of serum lactate dehydrogenase level in melanoma: A case report
复制标题
从达拉非尼/曲美替尼联合治疗转为恩科拉非尼/比尼美替尼联合治疗，黑色素瘤血清乳酸脱氢酶水平发生转变：病例报告
DOI：
10.1111/dth.15301
复制
发表时间：
2022
影响因子：
3.6
通讯作者：
Kono Michihiro
中科院分区：
文献类型：
--
作者：
Sato Takahiko;Noto Mai;Yamada Masayuki;Kono Michihiro
血清乳酸脱氢酶作为转移性黑色素瘤患者抗pd -1治疗预后的早期标志物在黑色素瘤辅助治疗中，仍然很难为每个患者选择最佳治疗方案，并找到避免治疗耐药性的最佳切换时机。初次手术6个月后，正电子发射断层扫描（PET-CT）和增强计算机断层扫描（CECT）显示多发远处淋巴结和内脏转移灶（图1D， F）。【文章摘自】Dermatologic Therapy版权归Hindawi Limited所有，未经版权所有者明确书面许可，不得将其内容复制或通过电子邮件发送到多个网站或发布到listserv。但是，用户可以打印、下载或通过电子邮件发送文章供个人使用。这篇摘要可以删节。对副本的准确性不作任何保证。用户应参考资料的原始出版版本以获取完整摘要。版权适用于所有摘要。
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. In melanoma adjuvant therapy, it is still difficult to choose the best therapy for each patient and to find the best timing for a switch that avoids treatment resistance. Six months after the initial operation, positron emission tomography-computed tomography (PET-CT) and contrast-enhanced computed tomography (CECT) revealed multiple distant LN and visceral metastases (Figure 1D, F).[Extracted from the article]Copyright of Dermatologic Therapy is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.